2021
DOI: 10.3390/biom11081072
|View full text |Cite
|
Sign up to set email alerts
|

Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies

Abstract: To date, vaccination has become one of the most effective strategies to control and reduce infectious diseases, preventing millions of deaths worldwide. The earliest vaccines were developed as live-attenuated or inactivated pathogens, and, although they still represent the most extended human vaccine types, they also face some issues, such as the potential to revert to a pathogenic form of live-attenuated formulations or the weaker immune response associated with inactivated vaccines. Advances in genetic engin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
62
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 91 publications
(62 citation statements)
references
References 255 publications
(328 reference statements)
0
62
0
Order By: Relevance
“…Production of malaria vaccine candidate antigens has been widely explored using different cell hosts ( Crosnier et al, 2013 ; Jones et al, 2013 ). Mammalian cells are an attractive option to produce therapeutic products requiring complex processing ( Dumont et al, 2016 ), but its use to produce recombinant protein vaccines can be more costly and yield lower expression levels than other expression systems ( Cid and Bolívar, 2021 ). Noteworthily, insect cells allow high production yields of mammalian-like recombinant proteins at reduced costs in short-time frames ( Mena and Kamen, 2011 ), having been successfully used to produce Rh5 ( Patel et al, 2013 ; Hjerrild et al, 2016 ).…”
Section: Introductionmentioning
confidence: 99%
“…Production of malaria vaccine candidate antigens has been widely explored using different cell hosts ( Crosnier et al, 2013 ; Jones et al, 2013 ). Mammalian cells are an attractive option to produce therapeutic products requiring complex processing ( Dumont et al, 2016 ), but its use to produce recombinant protein vaccines can be more costly and yield lower expression levels than other expression systems ( Cid and Bolívar, 2021 ). Noteworthily, insect cells allow high production yields of mammalian-like recombinant proteins at reduced costs in short-time frames ( Mena and Kamen, 2011 ), having been successfully used to produce Rh5 ( Patel et al, 2013 ; Hjerrild et al, 2016 ).…”
Section: Introductionmentioning
confidence: 99%
“…Nano-biomimetic delivery vehicles are made with pathogen antigens into nanovaccines, such as virus-like particles (VLPs), a virus-derived structure composed of one or more different molecules with the ability to self-assemble [ 82 , 83 ]. VLPs mimic the form and size of viruses, however, they lack genetic material, so they have high biological safety due to low infectious doses [ 84 , 85 ]. So far, a series of VLPs candidate vaccines against COVID-19 have been developed, and the effect is being evaluated.…”
Section: Nanovaccinesmentioning
confidence: 99%
“…Advantages provided by transgenic plants are the low cost of production, estimated to be 10 to 50 times lower than products derived from E. coli and 140 times lower than production using baculovirus-based insect cells [ 69 , 76 ], and the simple scaling-up that requires few materials except for cultivation surface. Since the plants are edible, they could also serve as delivery mode for oral vaccination, thereby reducing the purification costs.…”
Section: Various Systems Used To Produce Vlpsmentioning
confidence: 99%